These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37186162)

  • 1. Single-Dose Treatment With Vesicular Stomatitis Virus-Based Ebola Virus Vaccine Expressing Ebola Virus-Specific Artificial Micro-RNA Does Not Protect Mice From Lethal Disease.
    O'Donnell KL; Callison J; Feldmann H; Hoenen T; Marzi A
    J Infect Dis; 2023 Nov; 228(Suppl 7):S677-S681. PubMed ID: 37186162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
    Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA
    Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
    Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
    mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.
    Bushmaker T; Feldmann F; Lovaglio J; Saturday G; Griffin AJ; O'Donnell KL; Strong JE; Sprecher A; Kobinger G; Geisbert TW; Marzi A; Feldmann H
    J Infect Dis; 2023 Nov; 228(Suppl 7):S721-S729. PubMed ID: 37474155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
    Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
    Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine.
    Kasereka MC; Mumtaz Z; Hawkes MT
    Drugs Today (Barc); 2021 Jan; 57(1):27-45. PubMed ID: 33594388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preexisting Immunity Does Not Prevent Efficacy of Vesicular Stomatitis Virus-Based Filovirus Vaccines in Nonhuman Primates.
    Marzi A; Feldmann F; O'Donnell KL; Hanley PW; Messaoudi I; Feldmann H
    J Infect Dis; 2023 Nov; 228(Suppl 7):S671-S676. PubMed ID: 37290042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
    Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
    Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques.
    Marzi A; Fletcher P; Feldmann F; Saturday G; Hanley PW; Feldmann H
    Lancet Microbe; 2023 Mar; 4(3):e171-e178. PubMed ID: 36739878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
    Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
    Front Immunol; 2021; 12():703986. PubMed ID: 34484200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.
    Zhang X; Zhang T; Davis JN; Marzi A; Marchese AM; Robek MD; van den Pol AN
    J Virol; 2020 Mar; 94(8):. PubMed ID: 32051271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced
    Chabot S; Gimie Y; Obeid K; Kim J; Meseda CA; Konduru K; Kaplan G; Sheng Fowler L; Weir JP; Peden K; Major ME
    J Virol; 2022 Sep; 96(18):e0116621. PubMed ID: 36069549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 17. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
    Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2017 May; 91(10):. PubMed ID: 28250127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses.
    Saito T; Maruyama J; Nagata N; Isono M; Okuya K; Takadate Y; Kida Y; Miyamoto H; Mori-Kajihara A; Hattori T; Furuyama W; Ogawa S; Iida S; Takada A
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32842671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.
    Wong G; Qiu X
    Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.